Selective glutathione repletion with oral oxothiazolidine carboxylate (OTZ) in the radiated tumor-bearing rat

D. Michael Rose, Steven N. Hochwald, Lawrence Harrison, Michael Burt

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Oxothiazolidine carboxylate (OTZ) is a cysteine prodrug which augments intracellular glutathione (GSH) levels. We examined the effects of oral OTZ on tumor and host tissue reduced GSH levels in fasting and radiated models of GSH depletion. In addition, we studied the tumor's ability to utilize OTZ via the enzyme, oxoprolinase. Fischer 344 rats (n = 40) were implanted with MCA sarcoma and studied at 10% tumor burden. Treatment consisted of 10 mmol/kg OTZ or buffer orally. After a 24-hr fast, 16 animals were treated and tumor, kidney, jejunal, and colonic mucosa were collected after 4 hr. Significant increases in GSH with OTZ (n = 8) vs buffer (n = 8) were seen in kidney (5.6 ± 0.4 vs 4.3 ± 0.9; P < 0.01), jejunum (13.8 ± 1.3 vs 12.1 ± 1.1; P < 0.05), and colon (6.7 ± 1.2 vs 5.3 ± 0.6; P < 0.05), but not tumor (8.9 ± 2.4 vs 10.6 ± 1.4; P = 0.12). Sixteen animals were treated 4 hr before and 18 hr following 1100 cGy of abdominal radiation and at 4 days, tumor, jejunal, and colonic mucosa were collected. Significant increases in GSH with OTZ (n = 8) vs buffer (n = 8) were noted in jejunum (9.3 ± 1.1 vs 7.5 ± 1.8; P < 0.05) and colon (5.6 ± 1.1 vs 4.3 ± 0.9; P < 0.05) but not tumor (8.4 ± 1.6 vs 7.6 ± 1.4; P = 0.34). To determine tissue oxoprolinase activity, tumor, kidney, liver, jejunal, and colonic mucosa were collected from 8 animals. Oxoprolinase activity was highest in the kidney (814 ± 145) with no difference noted between liver and tumor (280 ± 117 and 324 ± 137, respectively). Oral OTZ selectively increases reduced GSH levels in normal tissues compared to tumor following fasting and whole abdominal radiation. This increase does not appear to be due to a differential activity of oxoprolinase. OTZ may have a role in protection against toxicity associated with oxidative injury by selective repletion of normal host tissue GSH levels.

Original languageEnglish (US)
Pages (from-to)224-228
Number of pages5
JournalJournal of Surgical Research
Volume62
Issue number2
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Glutathione
Pyroglutamate Hydrolase
Neoplasms
Kidney
Buffers
Mucous Membrane
Jejunum
Fasting
Colon
Radiation
Aptitude
Liver
Inbred F344 Rats
Prodrugs
Tumor Burden
Sarcoma
Cysteine
Wounds and Injuries
Enzymes

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

@article{0c5b44b757464498aed8e1ac7e02511f,
title = "Selective glutathione repletion with oral oxothiazolidine carboxylate (OTZ) in the radiated tumor-bearing rat",
abstract = "Oxothiazolidine carboxylate (OTZ) is a cysteine prodrug which augments intracellular glutathione (GSH) levels. We examined the effects of oral OTZ on tumor and host tissue reduced GSH levels in fasting and radiated models of GSH depletion. In addition, we studied the tumor's ability to utilize OTZ via the enzyme, oxoprolinase. Fischer 344 rats (n = 40) were implanted with MCA sarcoma and studied at 10{\%} tumor burden. Treatment consisted of 10 mmol/kg OTZ or buffer orally. After a 24-hr fast, 16 animals were treated and tumor, kidney, jejunal, and colonic mucosa were collected after 4 hr. Significant increases in GSH with OTZ (n = 8) vs buffer (n = 8) were seen in kidney (5.6 ± 0.4 vs 4.3 ± 0.9; P < 0.01), jejunum (13.8 ± 1.3 vs 12.1 ± 1.1; P < 0.05), and colon (6.7 ± 1.2 vs 5.3 ± 0.6; P < 0.05), but not tumor (8.9 ± 2.4 vs 10.6 ± 1.4; P = 0.12). Sixteen animals were treated 4 hr before and 18 hr following 1100 cGy of abdominal radiation and at 4 days, tumor, jejunal, and colonic mucosa were collected. Significant increases in GSH with OTZ (n = 8) vs buffer (n = 8) were noted in jejunum (9.3 ± 1.1 vs 7.5 ± 1.8; P < 0.05) and colon (5.6 ± 1.1 vs 4.3 ± 0.9; P < 0.05) but not tumor (8.4 ± 1.6 vs 7.6 ± 1.4; P = 0.34). To determine tissue oxoprolinase activity, tumor, kidney, liver, jejunal, and colonic mucosa were collected from 8 animals. Oxoprolinase activity was highest in the kidney (814 ± 145) with no difference noted between liver and tumor (280 ± 117 and 324 ± 137, respectively). Oral OTZ selectively increases reduced GSH levels in normal tissues compared to tumor following fasting and whole abdominal radiation. This increase does not appear to be due to a differential activity of oxoprolinase. OTZ may have a role in protection against toxicity associated with oxidative injury by selective repletion of normal host tissue GSH levels.",
author = "Rose, {D. Michael} and Hochwald, {Steven N.} and Lawrence Harrison and Michael Burt",
year = "1996",
month = "1",
day = "1",
doi = "10.1006/jsre.1996.0199",
language = "English (US)",
volume = "62",
pages = "224--228",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

Selective glutathione repletion with oral oxothiazolidine carboxylate (OTZ) in the radiated tumor-bearing rat. / Rose, D. Michael; Hochwald, Steven N.; Harrison, Lawrence; Burt, Michael.

In: Journal of Surgical Research, Vol. 62, No. 2, 01.01.1996, p. 224-228.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Selective glutathione repletion with oral oxothiazolidine carboxylate (OTZ) in the radiated tumor-bearing rat

AU - Rose, D. Michael

AU - Hochwald, Steven N.

AU - Harrison, Lawrence

AU - Burt, Michael

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Oxothiazolidine carboxylate (OTZ) is a cysteine prodrug which augments intracellular glutathione (GSH) levels. We examined the effects of oral OTZ on tumor and host tissue reduced GSH levels in fasting and radiated models of GSH depletion. In addition, we studied the tumor's ability to utilize OTZ via the enzyme, oxoprolinase. Fischer 344 rats (n = 40) were implanted with MCA sarcoma and studied at 10% tumor burden. Treatment consisted of 10 mmol/kg OTZ or buffer orally. After a 24-hr fast, 16 animals were treated and tumor, kidney, jejunal, and colonic mucosa were collected after 4 hr. Significant increases in GSH with OTZ (n = 8) vs buffer (n = 8) were seen in kidney (5.6 ± 0.4 vs 4.3 ± 0.9; P < 0.01), jejunum (13.8 ± 1.3 vs 12.1 ± 1.1; P < 0.05), and colon (6.7 ± 1.2 vs 5.3 ± 0.6; P < 0.05), but not tumor (8.9 ± 2.4 vs 10.6 ± 1.4; P = 0.12). Sixteen animals were treated 4 hr before and 18 hr following 1100 cGy of abdominal radiation and at 4 days, tumor, jejunal, and colonic mucosa were collected. Significant increases in GSH with OTZ (n = 8) vs buffer (n = 8) were noted in jejunum (9.3 ± 1.1 vs 7.5 ± 1.8; P < 0.05) and colon (5.6 ± 1.1 vs 4.3 ± 0.9; P < 0.05) but not tumor (8.4 ± 1.6 vs 7.6 ± 1.4; P = 0.34). To determine tissue oxoprolinase activity, tumor, kidney, liver, jejunal, and colonic mucosa were collected from 8 animals. Oxoprolinase activity was highest in the kidney (814 ± 145) with no difference noted between liver and tumor (280 ± 117 and 324 ± 137, respectively). Oral OTZ selectively increases reduced GSH levels in normal tissues compared to tumor following fasting and whole abdominal radiation. This increase does not appear to be due to a differential activity of oxoprolinase. OTZ may have a role in protection against toxicity associated with oxidative injury by selective repletion of normal host tissue GSH levels.

AB - Oxothiazolidine carboxylate (OTZ) is a cysteine prodrug which augments intracellular glutathione (GSH) levels. We examined the effects of oral OTZ on tumor and host tissue reduced GSH levels in fasting and radiated models of GSH depletion. In addition, we studied the tumor's ability to utilize OTZ via the enzyme, oxoprolinase. Fischer 344 rats (n = 40) were implanted with MCA sarcoma and studied at 10% tumor burden. Treatment consisted of 10 mmol/kg OTZ or buffer orally. After a 24-hr fast, 16 animals were treated and tumor, kidney, jejunal, and colonic mucosa were collected after 4 hr. Significant increases in GSH with OTZ (n = 8) vs buffer (n = 8) were seen in kidney (5.6 ± 0.4 vs 4.3 ± 0.9; P < 0.01), jejunum (13.8 ± 1.3 vs 12.1 ± 1.1; P < 0.05), and colon (6.7 ± 1.2 vs 5.3 ± 0.6; P < 0.05), but not tumor (8.9 ± 2.4 vs 10.6 ± 1.4; P = 0.12). Sixteen animals were treated 4 hr before and 18 hr following 1100 cGy of abdominal radiation and at 4 days, tumor, jejunal, and colonic mucosa were collected. Significant increases in GSH with OTZ (n = 8) vs buffer (n = 8) were noted in jejunum (9.3 ± 1.1 vs 7.5 ± 1.8; P < 0.05) and colon (5.6 ± 1.1 vs 4.3 ± 0.9; P < 0.05) but not tumor (8.4 ± 1.6 vs 7.6 ± 1.4; P = 0.34). To determine tissue oxoprolinase activity, tumor, kidney, liver, jejunal, and colonic mucosa were collected from 8 animals. Oxoprolinase activity was highest in the kidney (814 ± 145) with no difference noted between liver and tumor (280 ± 117 and 324 ± 137, respectively). Oral OTZ selectively increases reduced GSH levels in normal tissues compared to tumor following fasting and whole abdominal radiation. This increase does not appear to be due to a differential activity of oxoprolinase. OTZ may have a role in protection against toxicity associated with oxidative injury by selective repletion of normal host tissue GSH levels.

UR - http://www.scopus.com/inward/record.url?scp=0029923806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029923806&partnerID=8YFLogxK

U2 - 10.1006/jsre.1996.0199

DO - 10.1006/jsre.1996.0199

M3 - Article

VL - 62

SP - 224

EP - 228

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -